EX02 CAR-T cell therapy for advanced pancreatic or bile duct cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase trial tests a new treatment called EX02 CAR-T cells, which are your own immune cells modified to attack cancer cells. It is for people with pancreatic or bile duct cancer that cannot be removed by surgery or has spread, and who have tried at least one chemotherapy without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced pancreatic or bile duct cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer must have a specific marker called EX02 on the surface of its cells.
- You must have tried at least one round of chemotherapy that did not work or is no longer an option.
- You must be 18 years or older and in generally good health aside from your cancer.
- You cannot have had certain types of cell therapy before, like other CAR-T treatments.
- You must not have serious infections, heart problems, or other active major illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.